Conference
QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study
Authors
Gauvreau GM; Boulet L-P; Leigh R; Cockcroft DW; Davis BE; Mayers I; FitzGerald JM; Dahlen B; Watson RM; Milot J
Publisher
European Respiratory Society (ERS)
Publication Date
9 2015
DOI
10.1183/13993003.congress-2015.pa5091
Name of conference
5.3 Allergy and Immunology